WO2020170840A1 - 2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩結晶とその製造方法 - Google Patents
2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩結晶とその製造方法 Download PDFInfo
- Publication number
- WO2020170840A1 WO2020170840A1 PCT/JP2020/004590 JP2020004590W WO2020170840A1 WO 2020170840 A1 WO2020170840 A1 WO 2020170840A1 JP 2020004590 W JP2020004590 W JP 2020004590W WO 2020170840 A1 WO2020170840 A1 WO 2020170840A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ascorbic acid
- glucoside
- crystals
- crystal
- potassium salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a novel 2-O- ⁇ -D-glucosyl-L-ascorbic acid potassium salt crystal and a method for producing the same.
- ascorbic acid 2-glucoside has 1-position at the 2-position hydroxyl group of L-ascorbic acid (vitamin C) molecule. It is a compound in which D-glucose of the molecule is bound via an ⁇ -glucosidic bond. Unlike L-ascorbic acid, ascorbic acid 2-glucoside is also called “stable vitamin C” because it is non-reducing and has excellent stability. In addition, ascorbic acid 2-glucoside is easily hydrolyzed into L-ascorbic acid and D-glucose by an enzyme in the living body, and exhibits the physiological activity inherent in L-ascorbic acid.
- Ascorbic acid 2-glucoside causes cyclomaltodextrin glucanotransferase (hereinafter, abbreviated as “CGTase” in the present specification) to act on a solution containing starch and L-ascorbic acid, and further acts as glucoamylase. By doing so, it is manufactured on an industrial scale (see, for example, Patent Documents 1 to 3).
- High-purity anhydrous crystal-containing powder of 2-glucoside ascorbic acid is marketed by the present applicant under the trade name “AA2G” (registered trademark) for cosmetics and quasi-drugs. It is widely used in the field of quasi drugs.
- a powder containing anhydrous crystals of 2-glucoside ascorbic acid for foods and beverages is also marketed by the present applicant under the trade name "Asco Fresh" (registered trademark) (see, for example, Patent Documents 4 to 7). ).
- Patent Document 8 discloses a hydrous crystal of ascorbic acid 2-glucoside.
- Patent Document 9 two types of crystalline powder of aluminum salt of 2-glucoside ascorbic acid and crystalline powder of zinc salt of 2-glucoside ascorbic acid are used as crystals of metal salt of ascorbic acid 2-glucoside. It is disclosed.
- Patent Document 10 discloses water-containing crystals and anhydrous crystals of the sodium salt of ascorbic acid 2-glucoside.
- An object of the present invention is to provide a novel salt crystal of ascorbic acid 2-glucoside and a method for producing the same.
- the present inventors have dissolved ascorbic acid 2-glucoside in a potassium hydroxide aqueous solution at a specific concentration in the process of variously examining the crystallization conditions of ascorbic acid 2-glucoside to obtain alcohol. It was found that crystals were precipitated when added and allowed to stand. When the obtained crystals were subjected to HPLC analysis, only a peak of ascorbic acid 2-glucoside was observed. When subjected to a powder X-ray diffraction method, powder X-rays different from conventionally known crystals of ascorbic acid 2-glucoside were obtained. From the diffraction pattern, it was revealed that the crystals were novel ascorbic acid 2-glucoside crystals.
- the crystal contained a specific amount of potassium and water, it was found to be a water-containing crystal of potassium salt. Then, the present inventors have clarified the physical properties of the novel potassium salt crystal of 2-glucoside ascorbic acid and established the production method thereof to complete the present invention.
- the present invention solves the above-mentioned problems by providing a novel potassium salt crystal of 2-glucoside ascorbic acid and a method for producing the same.
- a novel potassium salt crystal of 2-glucoside ascorbic acid can be supplied.
- the crystal of the ascorbic acid 2-glucoside potassium salt of the present invention is used in combination with the ascorbic acid 2-glucoside anhydrous crystal to form a mixture, ascorbic acid exhibiting strong acidity is obtained by appropriately adjusting the mixing ratio of the two. Since the aqueous solution of the mixture can be adjusted to a desired pH range without neutralizing 2-glucoside with an alkali, it is suitable for producing foods and drinks, cosmetics, quasi drugs, pharmaceuticals, industrial products, etc. It can be used to advantage.
- FIG. 1 is an optical micrograph (magnification: 125 times) of a crystal obtained by adding methanol to an aqueous solution of potassium hydroxide of ascorbic acid 2-glucoside.
- FIG. 3 is a powder X-ray diffraction pattern of crystals obtained by adding methanol to an aqueous solution of potassium hydroxide of ascorbic acid 2-glucoside.
- FIG. 3 is a diagram comparing the powder X-ray diffraction pattern of the crystal shown in FIG. 2 with the powder X-ray diffraction pattern of anhydrous crystals of ascorbic acid 2-glucoside, hydrous crystals, and sodium salt crystals (hydrous crystals).
- FIG. 3 is an ORTEP diagram of hydrous crystals of ascorbic acid 2-glucoside potassium salt obtained by single crystal X-ray structural analysis.
- the present invention relates to crystals of potassium salt of ascorbic acid 2-glucoside.
- the ascorbic acid 2-glucoside potassium salt crystal of the present invention is a completely novel ascorbic acid 2-glucoside salt crystal, which was uniquely found by the present inventors, and is an ascorbic acid 2-glucoside potassium salt crystal. As long as it shows the physical properties and characteristics as crystals of ascorbic acid 2-glucoside potassium salt disclosed in the present specification, it is not limited to those produced by a specific production method.
- the potassium salt crystal of ascorbic acid 2-glucoside of the present invention has at least a powder X-ray diffraction pattern obtained by subjecting it to a powder X-ray diffraction method using CuK ⁇ rays as an X-ray source, as shown in the experimental section described later.
- Diffraction angles (2 ⁇ ) of 8.27°, 8.81°, 16.05°, 18.88°, and 25.64° are characteristic diffraction peaks.
- the crystals obtained in the present invention are It means that it is a crystal of ascorbic acid 2-glucoside different from the known crystal of ascorbic acid 2-glucoside.
- the potassium salt crystals of 2-glucoside ascorbic acid of the present invention usually have a water content of 12.5 to 14.8% by mass when measured by the conventional Karl Fischer method, as shown in the experimental section described later. Indicates. From this, it is understood that the potassium salt crystals of ascorbic acid 2-glucoside of the present invention are in the form of hydrous crystals.
- the ascorbic acid 2-glucoside potassium salt crystal of the present invention usually contains 14.1 to 14.6% by mass of potassium as measured by ion chromatography in the experimental section described later. From these results, it can be confirmed that the crystals of ascorbic acid 2-glucoside of the present invention are potassium salt crystals.
- the present inventors have succeeded in obtaining a single crystal having a size that enables single crystal X-ray crystal structure analysis, regarding the water-containing crystal of ascorbic acid 2-glucoside potassium salt.
- the present invention is also an invention which provides a novel method for producing crystals of potassium salt of 2-glucoside ascorbic acid.
- the method for producing hydrous crystals of ascorbic acid 2-glucoside potassium salt of the present invention is to dissolve ascorbic acid 2-glucoside as a raw material in a potassium hydroxide aqueous solution having a specific concentration, and then add a specific amount of alcohol at low temperature.
- a hydrous crystal of ascorbic acid 2-glucoside potassium salt can be produced by allowing the crystal to precipitate by allowing it to stand and then recovering the crystal using a solid-liquid separation method such as centrifugation.
- the origin of ascorbic acid 2-glucoside is not limited, and it may be one obtained by organic synthesis, but generally it is a conventionally known food or drink.
- ascorbic acid 2-glucoside for cosmetics and cosmetics that is, a solution containing high content of 2-glucoside ascorbic acid obtained by the method of causing CGTase to act on starch and L-ascorbic acid, and further to act on glucoamylase Quasi drug grade ascorbic acid 2-glucoside anhydrous crystal-containing powder (trade name "AA2G” (registered trademark), ascorbic acid 2-glucoside purity of 98% by mass or more, sold by Hayashibara Co., Ltd.), or food grade Ascorbic acid 2-glucoside anhydrous crystal-containing powder (trade name “Asco Fresh” (registered trademark), ascorbic acid 2-glucoside purity of 98% by mass or more, sold by Hayashibara Co., Ltd
- potassium hydroxide having a concentration of 4 to 8 N (N) is added to 1 mass of the anhydrous crystal of ascorbic acid 2-glucoside.
- Aqueous solution is added/dissolved at a ratio of 2 and then alcohol is added and mixed at a ratio of 3 or more, and the mixture is allowed to stand at a low temperature to precipitate water-containing crystals of potassium 2-glucoside ascorbate. ..
- anhydrous ascorbic acid 2-glucoside crystal when 1 g of anhydrous ascorbic acid 2-glucoside crystal is used, 2 mL of an aqueous potassium hydroxide solution having a concentration of 4 to 8 N (N) is added and dissolved, and then 3 mL or more of alcohol is added. It may be added, mixed, and allowed to stand at a low temperature.
- the molar ratio of potassium hydroxide to ascorbic acid 2-glucoside is usually preferably 2.7 to 5.4, more preferably 3.4 to 4.1.
- the alcohol to be added in the operation of precipitating crystals is not particularly limited, but methanol and ethanol widely used in this field can be preferably used.
- the final alcohol concentration during crystallization is preferably around 50% by volume.
- the precipitated crystals can be collected by a usual solid-liquid separation method such as filtration or centrifugation.
- the water-containing crystals of ascorbic acid 2-glucoside potassium salt obtained by the crystallization operation can be made into a higher-purity water-containing crystal by washing with an alcohol aqueous solution.
- the obtained water-containing crystals can be made into a powder containing water-containing crystals of ascorbic acid 2-glucoside potassium salt by pulverizing and drying if necessary.
- a water-containing crystal-containing powder of ascorbic acid 2-glucoside potassium salt can also be obtained by spray-drying a musket obtained by adding alcohol to precipitate crystals.
- One of the characteristics of the water-containing crystals of the potassium salt of 2-glucoside ascorbic acid of the present invention is that the resulting aqueous solution exhibits alkalinity when dissolved in water, and in this respect, known ascorbic acid 2- It is similar to the crystal of sodium salt of glucoside. This property is in sharp contrast with the fact that when anhydrous ascorbic acid 2-glucoside crystals are dissolved in water, the resulting aqueous solution exhibits relatively strong acidity. Therefore, the novel water-containing crystals of potassium salt of 2-glucoside ascorbic acid, which were created by the present inventors, cannot be used in the conventional ascorbic acid 2-glucoside anhydrous crystal because the aqueous solution exhibits relatively strong acidity.
- aqueous solution is used. It is essential to neutralize the acidic solution of ascorbic acid 2-glucoside dissolved in the medium in advance with an alkali and to add a buffering agent for pH adjustment, but to dissolve the water-containing crystals of ascorbic acid 2-glucoside potassium salt.
- the aqueous solution thus obtained usually shows alkalinity, and therefore, when blended into the external composition for skin, it is not necessary to use an alkali to neutralize ascorbic acid 2-glucoside, and a buffer may be used in combination. It is often unnecessary.
- compositions including the external composition for skin and the basic cosmetics, whose total pH is preferably in the range of weakly alkaline to weakly acidic can be produced without neutralization.
- ascorbic acid 2-glucoside anhydrous crystals and hydrous crystals of ascorbic acid 2-glucoside potassium salt are weighed in an amount according to their respective compounding ratios during the production of various compositions.
- ascorbic acid 2-glucoside anhydrous crystals and ascorbic acid 2-glucoside potassium salt hydrous crystals are blended in a predetermined mass ratio. It is convenient to keep the composition.
- the mass ratio can be arbitrarily set depending on the desired pH, but in order to set it in the weakly acidic to neutral range generally used for cosmetics and the like, the mass ratio is usually 70:30 to 45:55. It is preferable to mix it in the range of 50:50 to 45:55.
- the crystal of ascorbic acid 2-glucoside potassium salt of the present invention is a novel crystal form of ascorbic acid 2-glucoside, and is a known crystal form of ascorbic acid 2-glucoside sodium salt in that the pH of its aqueous solution shows alkalinity. It is the same. Crystals of ascorbic acid 2-glucoside potassium salt of the present invention also include foods and drinks and cosmetics containing ascorbic acid 2-glucoside, similar to conventionally known anhydrous crystals of ascorbic acid 2-glucoside, hydrous crystals, sodium salt crystals and the like. It can be advantageously used for manufacturing quasi drugs, pharmaceuticals, or industrial products.
- ⁇ Experiment 2-1 Crystal shape> Regarding the crystal obtained in Experiment 1, the shape of the crystal was observed using an optical microscope (BX-50 type, manufactured by Olympus Corporation). The crystal obtained in Experiment 1 had a size of 10 to 100 ⁇ m ⁇ 1000 ⁇ m. Its shape was columnar and transparent. Among the obtained crystals, a photomicrograph of a crystal that seems to be typical was taken (magnification: 125 times) and shown in FIG. The length of the scale bar shown in the lower right of FIG. 1 is 200 ⁇ m.
- Example 2-2 HPLC analysis> The crystals obtained in Experiment 1 were dissolved in deionized water to a final concentration of 1% by mass and subjected to HPLC analysis under the following conditions.
- a powder containing anhydrous crystals of 2-glucoside ascorbic acid (trade name "Asco Fresh” (registered trademark), sold by Hayashibara Co., Ltd.) was used and analyzed under the same conditions.
- Example 2-3 pH and UV absorption spectrum of aqueous solution in which crystals are dissolved>
- the pH was 12.7, which was alkaline.
- the aqueous solution was diluted 300-fold and the UV absorption spectrum was measured, it showed the same UV absorption spectrum ( ⁇ max 260 nm) as that of ascorbic acid 2-glucoside.
- ⁇ Experiment 2-4 powder X-ray diffraction pattern> The crystals obtained in Experiment 1 were subjected to powder X-ray diffraction analysis using a powder X-ray diffractometer (“X'Pert Pro MPD”, using CuK ⁇ ray, manufactured by Spectris Co., Ltd.). About 50 mg of a crystal sample was placed on a silicon non-reflective plate, irradiated with CuK ⁇ rays under the following conditions while rotating, and a powder X-ray diffraction pattern was obtained by a reflection method. The powder X-ray diffraction pattern obtained is shown in FIG. ⁇ CuK ⁇ ray irradiation conditions> X-ray tube current: 40 mA X-ray tube voltage: 45 kv Wavelength: 1.5405 ⁇
- FIG. 3 a powder X-ray diffraction pattern of the crystal obtained in Experiment 1, a powder X-ray diffraction pattern of a sodium salt crystal of ascorbic acid 2-glucoside (hydrous crystal, manufactured by Hayashibara Co., Ltd.), a powder of ascorbic acid 2-glucoside Powder X-ray diffraction pattern of hydrous crystal (Hayashibara preparation) and anhydrous crystal of ascorbic acid 2-glucoside (trade name "Asco Fresh” (registered trademark), sold by Hayashibara Co., Ltd.) Reference numerals A, B, C, and D respectively indicate.
- the newly obtained crystals have diffraction angles (2 ⁇ ) of 8.27°, 8.81°, 16.05°, 18.88°, and 25.64 in the powder X-ray diffraction pattern.
- characteristic diffraction peaks symbols a, b, c, d, and e in FIG. 2 are shown at .degree., and in addition, as is clear from FIG. This was completely different from the powder X-ray diffraction patterns of any of acid 2-glucoside anhydrous crystals, hydrous crystals and sodium salt crystals (hydrous crystals). From this result, it was found that the crystal obtained in Experiment 1 was a novel crystal of ascorbic acid 2-glucoside.
- ⁇ Experiment 2-6 Measurement of potassium content> 150 mg of the crystal obtained in Experiment 1 was weighed, dissolved in 100 mL of deionized water, and further diluted 50 times with deionized water to obtain a measurement sample. The amount of potassium in the sample was measured using an ion chromatograph (“DIONEX ICS-5000+”, manufactured by Thermo Fisher Scientific) under the following conditions.
- DIONEX ICS-5000+ manufactured by Thermo Fisher Scientific
- the potassium content of the crystals calculated based on the result of ion chromatography was 14.2% by mass. From this result, it was confirmed that the crystals of ascorbic acid 2-glucoside obtained in Experiment 1 were potassium salt crystals.
- Table 1 shows the crystal composition (mass %) calculated when potassium is assumed to exist as potassium hydroxide (KOH) in the crystal. Further, the results of calculating the molar ratio of 2-glucoside ascorbic acid to potassium hydroxide in that case are also shown in Table 1.
- the potassium content in the water-containing crystals of ascorbic acid 2-glucoside potassium salt is about 14.2% by mass, and assuming that all potassium exists in the form of potassium hydroxide (KOH), the potassium hydroxide content is It was calculated to be 20.4% by mass. In that case, when the mass of water 14.8 mass% and the mass of potassium hydroxide 20.4 mass% are subtracted from the crystal mass 100 mass %, the amount of ascorbic acid 2-glucoside occupies 64.8 mass %. When the molar ratio of ascorbic acid 2-glucoside to potassium hydroxide is calculated based on this numerical value, as shown in Table 1, it is 1.0:1.90. Therefore, the hydrous crystal of the ascorbic acid 2-glucoside potassium salt is obtained. Was estimated to contain approximately 2 molecules of potassium hydroxide per molecule of ascorbic acid 2-glucoside, assuming that all potassium was present in the form of potassium hydroxide.
- the water content of the water-containing crystals of ascorbic acid 2-glucoside potassium salt is about 14.8 mass %, and the molar ratio of ascorbic acid 2-glucoside to water molecules is about 1.0:4.3. From this, it was estimated that the water-containing crystals of the potassium salt of 2-glucoside ascorbic acid contained 4 molecules of water of crystallization for 1 molecule of 2-glucoside ascorbic acid.
- ascorbic acid 2-glucoside anhydrous crystal-containing powder was dissolved in 4N, 5N, 6N, and 8N potassium hydroxide aqueous solutions having different concentrations, and methanol was added to the potassium hydroxide aqueous solution.
- Precipitation of crystals of potassium salt of acid 2-glucoside was observed.
- the molar ratio of potassium hydroxide to 2-glucoside ascorbic acid precipitation of crystals was observed in the molar ratio range of 2.7 to 5.4.
- the potassium hydroxide concentration was 3 N or less and the molar ratio of potassium hydroxide to ascorbic acid 2-glucoside was 2.0 or less, no precipitation of crystals was observed.
- the potassium hydroxide concentration was 10 N or more and the molar ratio of potassium hydroxide to 2-glucoside ascorbic acid was 6.8 or more, no precipitation of crystals was observed and the sample was colored. ..
- Patent Document 10 discloses a method for producing sodium salt crystals of ascorbic acid 2-glucoside. According to this method, the molar ratio of sodium hydroxide to ascorbic acid 2-glucoside is 1.7 or more, and ascorbic acid. Precipitation of crystals was observed when the amount of methanol per 1 g of 2-glucoside was 1 mL.
- the present inventors used the same method as the sodium salt crystals disclosed in Patent Document 10 except that sodium hydroxide was first replaced with potassium hydroxide. Attempts were made under precipitation conditions, but crystals of potassium salt could not be obtained.
- the pH of the aqueous solution in which ascorbic acid 2-glucoside anhydrous crystal-containing powder was dissolved alone (100% by mass) to a concentration of 1% by mass was 2.2, while ascorbic acid 2
- the aqueous solution of glucoside potassium salt dissolved alone (100% by mass) to a concentration of 1% by mass had a pH of 12.7.
- the relative mixing ratio of the powder containing anhydrous crystals of 2-glucoside ascorbic acid and the water-containing crystals of potassium salt of 2-glucoside ascorbic acid was changed within the range of 90:10 to 10:90 to prepare an aqueous solution having a concentration of 1% by mass.
- the pH was in the range of 2.5 to 12.6.
- the weight-increasing rate of the water-containing crystals of ascorbic acid 2-glucoside potassium salt and the water-containing crystals of ascorbic acid 2-glucoside sodium salt were 9.1% by mass and 15.8% by mass, respectively. It was found that all of them absorb moisture under the condition of relative humidity (RH) of 75.2%.
- the mass increase rate of water-containing crystals of ascorbic acid 2-glucoside potassium salt is slightly less than 60% of that of water-containing crystals of ascorbic acid 2-glucoside sodium salt, and the water-containing crystal of ascorbic acid 2-glucoside potassium salt is ascorbic acid 2-glucoside.
- the hygroscopicity was lower than that of the water-containing crystals of sodium salt.
- Table 5 shows the crystallographic parameters of hydrous crystals of ascorbic acid 2-glucoside potassium salt obtained by single crystal X-ray crystal structure analysis.
- hydrous crystalline potassium salt of ascorbic acid 2-glucoside molecular formula C 12 H 24 K 2 O 15 , formula C 12 H 17 O 11 - ⁇ 2K + ⁇ OH - It was considered to have a molecular weight of 486.51 at 3H 2 O.
- the crystal is composed of 1 molecule of ascorbic acid 2-glucoside in which hydrogen is dissociated from the 3-position hydroxyl group of L-ascorbic acid, 2 potassium ions, 1 hydroxide ion, and 3 molecules of water. It was presumed to be a crystal.
- ⁇ Hydrohydrate crystals of ascorbic acid 2-glucoside potassium salt Completely by adding 1 kg of commercially available powder containing anhydrous 2-glucoside ascorbic acid crystals (trade name “AA2G” (registered trademark), purity 98% by mass or more, sold by Hayashibara Co., Ltd.) to 2 L of 5N potassium hydroxide aqueous solution and stirring. Dissolved in. To this aqueous solution, 3 L of methanol was added and mixed, and 10 g of water-containing crystals of ascorbic acid 2-glucoside potassium salt prepared in advance by the method of Experiment 1 was added as a seed crystal, stirred and mixed, and then at 5° C. It was left to stand for 3 days for crystallization.
- A2G anhydrous 2-glucoside ascorbic acid crystals
- the obtained crystals were collected by filtration, washed with a 60% by volume aqueous methanol solution, and dried at 30° C. to produce about 1.1 kg of water-containing crystals of ascorbic acid 2-glucoside potassium salt.
- the purity of ascorbic acid 2-glucoside in this crystal was 99.2% by mass measured by the HPLC method described in Experiment 2-2, and the water content was measured by the Karl Fischer method at 12.5% by mass.
- the potassium content of the crystal calculated based on the result of ion chromatography was 14.1% by mass.
- This product is a hydrous crystalline product of ascorbic acid 2-glucoside potassium salt with good flowability, and can be widely used advantageously in various compositions such as food and drink, cosmetics, quasi drugs, and pharmaceuticals.
- an enzyme agent of CGTase derived from Geobacillus stearothermophilus manufactured by Hayashibara Co., Ltd.
- was added in an amount of 100 units per 1 g of tapioca starch solid was added in an amount of 100 units per 1 g of tapioca starch solid, and the mixture was reacted at 55° C. for 50 hours to obtain 2-glucoside ascorbic acid and 2- Glycoside was formed.
- glucoamylase agent (trade name “Glucozyme #20000”, 20,000 units/g, Nagase Chemtex Co., Ltd.) 50 units per 1 g of starch solids were added and reacted at 55° C. for 24 hours to decompose ascorbic acid 2-glycoside to ascorbic acid 2-glucoside and mixed sugars to glucose.
- the content of 2-glucoside ascorbic acid in this reaction solution was about 30.5% by mass in terms of anhydride.
- composition of the recovered ascorbic acid 2-glucoside-containing solution was 95.3% by mass of ascorbic acid 2-glucoside, 1.2% by mass of L-ascorbic acid, 2.5% by mass of glucose, and 1.0% by mass in terms of anhydride. %Met.
- the solution containing 2-glucoside ascorbic acid is concentrated under reduced pressure to a solid concentration of about 60% by mass, potassium hydroxide is added and dissolved to a final concentration of 5 N, and ethanol is further added to a final concentration of 60% by volume.
- the crystals were collected by applying a basket type centrifuge to the crystals in a conventional manner, and the crystals were washed by spraying a small amount of 75% by volume aqueous ethanol solution, then pulverized and dried to give water-containing crystals of potassium 2-glucoside ascorbate. A powder containing was obtained.
- the purity of ascorbic acid 2-glucoside of this product was 98.6% by mass in terms of anhydride, and the water content was measured by the Karl Fischer method to be 14.3% by mass, based on the result of ion chromatography.
- the calculated potassium content of the crystals was 14.1% by mass.
- This product is a powdered product containing water-containing crystals of ascorbic acid 2-glucoside potassium salt with good flowability, and can be widely used for various compositions such as food and drink, cosmetics, quasi drugs, and pharmaceuticals.
- ⁇ Blend of ascorbic acid 2-glucoside potassium salt water-containing crystal and ascorbic acid 2-glucoside anhydrous crystal 50 parts by weight of water-containing crystals of ascorbic acid 2-glucoside potassium salt obtained by the method of Example 1 was used, and ascorbic acid 2-glucoside anhydrous crystal-containing powder (trade name “AA2G” (registered trademark), sold by Hayashibara Co., Ltd.) 50 The parts by mass were uniformly mixed, pulverized and dried to obtain a powdery compound.
- This product is a mixture of water-containing crystals of ascorbic acid 2-glucoside potassium salt and commonly-used anhydrous ascorbic acid 2-glucoside crystals.
- As with conventional powders containing ascorbic acid 2-glucoside anhydrous crystals it is used as a cosmetic material. Also, it can be advantageously used as a material for quasi drugs, pharmaceuticals, foods and the like.
- the aqueous solution of this product exhibits weak acidity, it can be easily adjusted to a desired pH as compared with the case of using the conventional powder containing anhydrous crystals of 2-glucoside ascorbic acid.
- a skin lotion was prepared by dissolving the components (1) to (4) of the above-mentioned formulation in purified water (9), and then gradually adding and mixing the mixture of the components (5) to (8).
- This product is a lotion containing ascorbic acid 2-glucoside, and has not only anti-wrinkle and anti-wrinkle effects, but also whitening effect, anti-stain, anti-sagging effect, skin barrier function and hyaluronic acid production. It is useful as a lotion for anti-aging, which is also excellent in maintaining or enhancing the action of. Further, since it is blended with 1,2-pentanediol, it is a lotion having excellent antiseptic effects and moisturizing properties, low irritation to the skin, and excellent stability.
- This product is a beauty essence containing 2-glucoside ascorbic acid, which has a stable anti-wrinkle effect and anti-wrinkle effect, and also has an excellent whitening effect and an excellent anti-aging beauty essence. It is useful.
- ⁇ Health supplements > 1 part by mass of the compound obtained by the method of Example 3 and 99 parts by mass of trehalose (trade name “Treha” (registered trademark), sold by Hayashibara Co., Ltd.) were uniformly mixed, and then 50 g each was filled in a glass bottle to obtain a product. ..
- the product is useful as a dietary supplement enriched with vitamin C.
- 3 parts by mass, powdered saccharide-transferred hesperidin 4 parts by mass, and purified water 2 parts by mass were put in a preparation tank and heated to 55° C. with stirring to be completely dissolved. Then, the mixture was homogenized according to a conventional method, sterilized by a sterilization cooler, inoculated with 3% by mass of a starter, filled in a plastic container, and then fermented at 37° C. for 5 hours to obtain a yogurt-type health food.
- This product is a yogurt-type health food fortified with vitamin C.
- ⁇ Vitamin C powder formulation> Using the composition obtained by the method of Example 3 as a powdered food material, 70 parts by mass of sucrose, 10 parts by mass of dextrin and an appropriate amount of flavors were added, and the mixture was stirred and mixed using a mixer to produce a vitamin C powder preparation. did.
- the crystalline powder of 2-glucoside ascorbic acid and other powders could be easily and uniformly mixed using a mixer, and could be produced without any trouble in the production process.
- This product is a Vitamin C powder formulation that can be easily mixed with other food and drink ingredients and does not easily brown or solidify even after long-term storage. Since this product and a composition containing this product have the physiological function of vitamin C, they can be orally taken for the purpose of maintaining the health of skin and mucous membranes and whitening.
- An ointment was prepared by adding 0.5 part by mass, 1 part by mass of the compound obtained by the method of Example 3 and 0.5 part by mass of mint oil, and further uniformly mixing.
- This product can be used advantageously as a sunscreen, skin beautifying agent, skin lightening agent, etc., and also as a healing accelerator for wounds and burns.
- the water-containing crystal of the ascorbic acid 2-glucoside potassium salt of the present invention is a new crystalline form of ascorbic acid 2-glucoside which has not been known so far.
- the ascorbic acid 2-glucoside potassium salt of the present invention can be treated with an alkali by adjusting the compounding ratio of both. Since the pH of the product can be adjusted to a desired range without being harmed, there is an advantage that foods and drinks, cosmetics, quasi drugs, pharmaceuticals, industrial products, etc. can be easily manufactured with a small number of steps. To be The present invention has such excellent advantages and has great industrial utility.
- FIG. ⁇ Five characteristic diffraction peaks a in the powder X-ray diffraction diagram of the crystal: a diffraction peak at a diffraction angle (2 ⁇ ) 8.27° b: a diffraction peak at a diffraction angle (2 ⁇ ) 8.81° c: diffraction angle ( 2 ⁇ ) 16.05° diffraction peak d: diffraction angle (2 ⁇ ) 18.88° diffraction peak e: diffraction angle (2 ⁇ ) 25.64° diffraction peak
- b a diffraction peak at a diffraction angle (2 ⁇ ) 8.81°
- c diffraction angle ( 2 ⁇ ) 16.05° diffraction peak
- d diffraction angle (2 ⁇ ) 18.88° diffraction peak
- e diffraction angle (2 ⁇ ) 25.64° diffraction peak
- A Powder X-ray diffraction pattern of newly obtained crystal
- B Powder X-ray diffraction diagram of ascorbic acid 2-glucoside sodium salt (hydrated crystal)
- C Powder of water-containing crystal (2-hydrated) of ascorbic acid 2-glucoside X-ray diffraction pattern
- D Powder X-ray diffraction pattern of anhydrous 2-glucoside ascorbic acid crystals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
市販のアスコルビン酸2-グルコシド無水結晶含有粉末(商品名『アスコフレッシュ』(登録商標)、株式会社林原販売)12gを、5Nの水酸化カリウム水溶液24mLに溶解させた後、この水溶液にさらにメタノールを36mL加えて攪拌し、4℃で4日間静置したところ、白濁が認められ、顕微鏡観察したところ結晶の析出が認められた。結晶懸濁液を、桐山ロート(東洋ろ紙No.5を使用)を用いて濾過することにより結晶を回収し、脱イオン水で洗浄した後、30℃で5時間真空乾燥し、約15.4gの結晶粉末を得た。前記水溶液中のアスコルビン酸2-グルコシドに対する水酸化カリウムのモル比は3.4であった。
実験1で取得した結晶について、結晶形状を顕微鏡観察するとともに、HPLC分析、水溶液のpH、UV吸収スペクトルの測定、粉末X線回折図、水分含量、及び、カリウム含量の各種測定を行った。
実験1で取得した結晶について、光学顕微鏡(BX-50型、オリンパス株式会社製)を用いて結晶の形状を観察したところ、実験1で取得した結晶は、10~100μm×1000μmの大きさで、その形状は柱状・透明であった。得られた結晶のうち、典型的と思われる結晶の顕微鏡写真を撮影(倍率125倍)し、図1に示した。なお、図1右下に示したスケールバーの長さは200μmである。
実験1で取得した結晶を、脱イオン水に終濃度1質量%となるように溶解し、下記の条件によるHPLC分析に供した。対照として、食品級のアスコルビン酸2-グルコシド無水結晶含有粉末(商品名『アスコフレッシュ』(登録商標)、株式会社林原販売)を用い、同条件で分析した。
<HPLC分析条件>
カラム:Wakopak Wakobeads T-330
(内径10mm×長さ300mm)H型 28901(和光純薬工業株式会社販売)
溶離液:0.0001N硝酸水溶液
流速:0.4mL/分
温度:室温
検出器:示差屈折計
実験1で取得した結晶を1質量%水溶液としてそのpHを測定したところ、pHは12.7とアルカリ性を示した。また、該水溶液を300倍希釈してUV吸収スペクトルを測定したところ、アスコルビン酸2-グルコシドと同一のUV吸収スペクトル(λmax 260nm)を示した。
実験1で取得した結晶を、粉末X線回折装置(『X‘Pert Pro MPD』、CuKα線使用、スペクトリス株式会社製)を用いた粉末X線回折分析に供した。結晶試料約50mgをシリコン製無反射板にのせ、回転させながら下記の条件にてCuKα線を照射し、反射法で粉末X線回折図を求めた。得られた粉末X線回折図を図2に示した。
<CuKα線照射条件>
X線管電流:40mA
X線管電圧:45kv
波長:1.5405Å
実験1で取得した結晶について、カールフィッシャー水分測定装置(商品名「AQ-2200」、平沼産業株式会社製)にて水分含量を測定したところ、14.8質量%であった。この結果から、実験1で取得したアスコルビン酸2-グルコシドの新規結晶は含水結晶の形態にあることが判明した。
実験1で取得した結晶を150mg秤取し、100mLの脱イオン水に溶解し、さらに脱イオン水で50倍希釈して測定試料とした。試料中のカリウム量をイオンクロマトグラフ(『DIONEX ICS-5000+』、サーモフィッシャーサイエンティフィック社製)を用い、下記の条件で測定した。
<測定条件>
カラム:Dionex IonPac CS16 (5×250mm)(サーモフィッシャーサイエンティフィック社製)
ガードカラム:Dionex IonPac CS16 Guard (5×50mm)(サーモフィッシャーサイエンティフィック社製)
溶離液:30mM メタンスルホン酸
流速:1.0mL/分
カラム温度:40℃
検出器:電気伝導度検出器
サプレッサー:電界再生型 CERS-500
電流:89mA
検出器コンパートメント温度:20℃
試料注量:25μL
標準液:陽イオン混合標準液II(6種)IC用 No.07197-96(関東化学株式会社製)
アスコルビン酸2-グルコシド無水結晶含有粉末(商品名『アスコフレッシュ』(登録商標)、株式会社林原販売)1gに対し、下記表2に示す1乃至10Nの水酸化カリウム水溶液を2mL添加し、溶解させた後、メタノールを3mL添加、混合し、混合液を4℃で24時間放置し結晶の析出の程度を目視にて調べた。結晶析出の程度は、
「-」:結晶が析出せず
「+」:結晶が僅かに析出
「++」:結晶が混合液容量の半分程度析出
「+++」:結晶が全体に析出し固化
の4段階に分けて判定した。結果を表2に示した。
市販のアスコルビン酸2-グルコシド無水結晶含有粉末(商品名『アスコフレッシュ』(登録商標)、株式会社林原販売)と実験1の方法で得たアスコルビン酸2-グルコシドカリウム塩の含水結晶を下記表3に示す100:0乃至0:100の質量比で配合して得られた各配合物を濃度1質量%になるように脱イオン水にそれぞれ溶解し、得られた水溶液のpHを測定した。結果を表3に示した。
実験1の方法で得たアスコルビン酸2-グルコシドカリウム塩の含水結晶と、前記した特許文献10記載の方法で得たアスコルビン酸2-グルコシドナトリウム塩の含水結晶について、両者の吸湿性を比較する実験を行った。すなわち、アスコルビン酸2-グルコシドカリウム塩の含水結晶及びアスコルビン酸2-グルコシドナトリウム塩の含水結晶のそれぞれ0.5gを秤取し、飽和食塩水溶液で相対湿度(RH)75.2%に調湿したデシケーター内に室温で24時間保存した後にそれぞれの質量を測定し、吸湿により増加した質量を求め、質量増加率{(保存により増加した質量/保存開始時の質量)×100}(質量%)を求めた。結果を表4に示した。
単結晶X線結晶構造解析に使用できる比較的大きな結晶を得るために、通常よりも結晶が析出し難い条件で時間をかけて結晶化を行った。すなわち、アスコルビン酸2-グルコシド無水結晶含有粉末(商品名『アスコフレッシュ』(登録商標)、株式会社林原販売)1gを通常の結晶化よりも濃度の薄い4Nの水酸化カリウム水溶液2mLに溶解させた後、メタノールを3mL添加、混合し、晶析に4日間かけて、アスコルビン酸2-グルコシドカリウム塩の含水結晶を析出させた。得られた結晶から適切な大きさのもの(0.30×0.09×0.07mm)を選択し、X線回折装置(『RIGAKU VariMax with Saturn 724』、株式会社リガク製)を用い、下記の条件にてX線回折パターンを測定した。解析ソフトには『Crystal Clear』(株式会社リガク製)を用いた。
<測定条件>
入射X線:MoKα線(波長0.71075Å)
出力:50kv、24mA
検出器:イメージングプレート
測定温度:約-173℃(窒素ガス吹き付け法)
市販のアスコルビン酸2-グルコシド無水結晶含有粉末(商品名『AA2G』(登録商標)、純度98質量%以上、株式会社林原販売)1kgを2Lの5N水酸化カリウム水溶液に加え、攪拌することにより完全に溶解した。この水溶液に3Lのメタノールを添加、混合し、予め実験1の方法で調製しておいたアスコルビン酸2-グルコシドカリウム塩の含水結晶を種晶として10g添加し、攪拌・混合した後、5℃で3日間放置することにより晶析させた。次いで、得られた結晶をろ過することにより回収し、60体積%メタノール水溶液で洗浄し、30℃で乾燥することにより、約1.1kgのアスコルビン酸2-グルコシドカリウム塩の含水結晶を製造した。本結晶におけるアスコルビン酸2-グルコシド純度を実験2-2記載のHPLC法にて測定したところ99.2質量%であり、また、カールフィッシャー法により水分含量を測定したところ、12.5質量%であり、イオンクロマトグラフィーの結果に基づき算出した結晶のカリウム含量は14.1質量%であった。
タピオカ澱粉7質量部を水25質量部に加え、市販の液化酵素を加え加熱溶解した後、L-アスコルビン酸3質量部を加え、pHを5.5に調整し基質溶液とした。これに、ジオバチルス・ステアロサーモフィルス由来CGTaseの酵素剤(株式会社林原製)を、タピオカ澱粉固形物1g当り100単位加えて55℃で50時間反応させ、アスコルビン酸2-グルコシド及びアスコルビン酸2-グリコシドを生成させた。
実施例1の方法で得たアスコルビン酸2-グルコシドカリウム塩の含水結晶50質量部に対し、アスコルビン酸2-グルコシド無水結晶含有粉末(商品名『AA2G』(登録商標)、株式会社林原販売)50質量部を均一に混合し、粉砕、乾燥して粉末状の配合物を得た。
(配合処方)
配合成分 (質量%)
(1)グリセリン 4.0
(2)プロピレングリコール 3.0
(3)1,2-ペンタンジオール 0.1
(4)実施例3の方法で得た配合物 2.0
(5)ポリオキシエチレン(20モル)オレインアルコール 0.5
(6)ユキノシタエキス 2.0
(7)エタノール 5.0
(8)香料 適量
(9)精製水 残量
(配合処方)
配合成分(質量%)
(1)マルチトール 7.5
(2)実施例3の方法で得た配合物 3.0
(3)1,2-アルカンジオール 5.0
(4)ポリエチレングリコール1500 1.0
(5)エタノール 5.0
(6)カルボキシビニルポリマー 0.4
(7)ポリアクリル酸ナトリウム 0.1
(8)ポリオキシエチレンオレイルエーテル(20E.O.) 1.5
(9)オリーブ油 0.2
(10)グリチルリチン酸ジカリウム 0.1
(11)水酸化カリウム 適量
(12)香料 適量
(13)精製水 残量
実施例3の方法で得た配合物1質量部とトレハロース(商品名『トレハ』(登録商標)、株式会社林原販売)99質量部を均一に混合した後、ガラス瓶に50gずつ充填した製品とした。本品は、ビタミンCが強化された健康補助食品として有用である。
脱脂乳85質量部、脱脂粉乳3質量部、トレハロース(商品名『トレハ』(登録商標)、株式会社林原販売)6質量部、寒天0.1質量部、実施例3の方法で得た配合物3質量部、粉末糖転移ヘスペリジン4質量部、及び精製水2質量部を調合タンクに入れ、攪拌しながら55℃に加熱して完全に溶解した。次いで、常法にしたがって混合物を均質化し、殺菌冷却器により殺菌し、スターターを3質量%接種し、プラスチック容器に充填した後、37℃で5時間発酵させてヨーグルトタイプの健康食品を得た。本品は、ビタミンCが強化されたヨーグルトタイプの健康食品である。
実施例3の方法で得た配合物を粉末状食品素材として用い、これにショ糖70質量部、デキストリン10質量部、適量の香料を加え、混合機を用い撹拌混合しビタミンC粉末製剤を製造した。アスコルビン酸2-グルコシドの結晶粉末と他の粉末とは、混合機を用い容易に均一に混合することができ、製造工程上何ら支障なく製造することができた。
酢酸ナトリウム・三水塩1質量部、DL-乳酸カルシウム4質量部をグリセリン10質量部と均一に混合し、この混合物を、ワセリン50質量部、木ロウ10質量部、ラノリン10質量部、ゴマ油14.5質量部、実施例3の方法で得た配合物1質量部及びハッカ油0.5質量部の混合物に加えて、更に均一に混和して軟膏を製造した。
↓:結晶の粉末X線回折図における特徴的な5つの回折ピーク
a:回折角(2θ)8.27°の回折ピーク
b:回折角(2θ)8.81°の回折ピーク
c:回折角(2θ)16.05°の回折ピーク
d:回折角(2θ)18.88°の回折ピーク
e:回折角(2θ)25.64°の回折ピーク
図3において、
A:新たに取得した結晶の粉末X線回折図
B:アスコルビン酸2-グルコシドナトリウム塩(含水結晶)の粉末X線回折図
C:アスコルビン酸2-グルコシドの含水結晶(1/2含水)の粉末X線回折図
D:アスコルビン酸2-グルコシド無水結晶の粉末X線回折図
Claims (9)
- 2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩の結晶。
- 粉末X線回折図において、少なくとも、回折角(2θ)8.27°、8.81°、16.05°、18.88°、及び、25.64°に回折ピークを示す請求項1記載の2-O-α-D-グルコシルL-アスコルビン酸のカリウム塩の結晶。
- 含水結晶の形態にある請求項1又は2記載の2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩の結晶。
- 2-O-α-D-グルコシル-L-アスコルビン酸を水酸化カリウム水溶液に溶解し、この水溶液にアルコールを添加して静置し、析出した2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩の結晶を採取することを特徴とする請求項1乃至3のいずれかに記載の2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩の結晶の製造方法。
- 前記水溶液中の2-O-α-D-グルコシル-L-アスコルビン酸に対する水酸化カリウムのモル比が2.7乃至5.4である請求項4記載の2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩の結晶の製造方法。
- アルコールが、メタノール又はエタノールである請求項4又は5記載の2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩の結晶の製造方法。
- 請求項1乃至3のいずれかに記載の2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩の結晶を含む組成物。
- 2-O-α-D-グルコシル-L-アスコルビン酸の無水結晶を含み、2-O-α-D-グルコシル-L-アスコルビン酸の無水結晶と、2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩の結晶の配合比が、質量比で70:30乃至45:55の範囲にある請求項7記載の組成物。
- 飲食品、化粧品、医薬部外品、医薬品、又は工業用品の形態にある請求項7又は8記載の組成物。
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021501848A JPWO2020170840A1 (ja) | 2019-02-20 | 2020-02-06 | 2−O−α−D−グルコシル−L−アスコルビン酸のカリウム塩結晶とその製造方法 |
| EP20759454.0A EP3928626A4 (en) | 2019-02-20 | 2020-02-06 | POTASSIUM SALT CRYSTAL OF 2-O-ALPHA-D-GLUCOSYL-L-ASCORBIC ACID AND PROCESS FOR ITS PRODUCTION |
| CN202080028448.8A CN113677211A (zh) | 2019-02-20 | 2020-02-06 | 2-O-α-D-葡糖基-L-抗坏血酸的钾盐晶体及其制备方法 |
| US17/431,825 US12338264B2 (en) | 2019-02-20 | 2020-02-06 | Crystalline potassium salt of 2-O-α-D-glucosyl-L-ascorbic acid and method for producing the same |
| CN202411931102.5A CN119751523A (zh) | 2019-02-20 | 2020-02-06 | 2-O-α-D-葡糖基-L-抗坏血酸的钾盐晶体及其制备方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019-028755 | 2019-02-20 | ||
| JP2019028755 | 2019-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020170840A1 true WO2020170840A1 (ja) | 2020-08-27 |
Family
ID=72143844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2020/004590 Ceased WO2020170840A1 (ja) | 2019-02-20 | 2020-02-06 | 2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩結晶とその製造方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12338264B2 (ja) |
| EP (1) | EP3928626A4 (ja) |
| JP (1) | JPWO2020170840A1 (ja) |
| CN (2) | CN119751523A (ja) |
| TW (1) | TW202045187A (ja) |
| WO (1) | WO2020170840A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023127882A1 (ja) * | 2021-12-28 | 2023-07-06 | コスメディ製薬株式会社 | スキンケア用皮膚適用組成物 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5856963B2 (ja) | 1977-05-06 | 1983-12-17 | 三菱化成ポリテック株式会社 | 電子発光化合物半導体の製造方法 |
| JPS637444B2 (ja) | 1980-06-30 | 1988-02-17 | Nissin Electric Co Ltd | |
| JPH03135992A (ja) | 1989-10-21 | 1991-06-10 | Hayashibara Biochem Lab Inc | 結晶2―O―α―D―グルコピラノシル―L―アスコルビン酸とその製造方法並びに用途 |
| JPH03139288A (ja) | 1989-05-19 | 1991-06-13 | Hayashibara Biochem Lab Inc | α―グリコシル―L―アスコルビン酸とその製造方法並びに用途 |
| JPH0446112A (ja) | 1990-06-11 | 1992-02-17 | Hayashibara Biochem Lab Inc | 養毛剤 |
| JPH04182419A (ja) | 1990-11-19 | 1992-06-30 | Hayashibara Biochem Lab Inc | 口腔用組成物 |
| JPH04182413A (ja) | 1990-11-19 | 1992-06-30 | Hayashibara Biochem Lab Inc | 皮膚外用剤 |
| JPH04182412A (ja) | 1990-11-19 | 1992-06-30 | Hayashibara Biochem Lab Inc | 皮膚外用剤 |
| JP3290490B2 (ja) | 1993-01-25 | 2002-06-10 | 株式会社林原生物化学研究所 | アスコルビン酸−2−O−α−グルコシドの金属塩およびその医薬用途 |
| WO2014104171A1 (ja) * | 2012-12-27 | 2014-07-03 | 株式会社林原 | アンチエイジング用皮膚外用組成物及びその製造方法 |
| WO2018021542A1 (ja) * | 2016-07-29 | 2018-02-01 | カーリットホールディングス株式会社 | 2-O-α-D-グリコシル-L-アスコルビン酸金属塩、その酸化防止剤としての用途及びその粉末の製造方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE123306T1 (de) | 1989-05-19 | 1995-06-15 | Hayashibara Biochem Lab | Alpha-glycosyl-l-ascorbinsäure und ihre herstellung und verwendungen. |
| TW197375B (ja) | 1990-11-19 | 1993-01-01 | Hayashibara Biochem Lab | |
| WO2012033218A1 (ja) | 2010-09-07 | 2012-03-15 | 株式会社林原生物化学研究所 | 2−O−α−D−グルコシル−L−アスコルビン酸含水結晶及び2−O−α−D−グルコシル−L−アスコルビン酸含水結晶含有粉末とそれらの製造方法並びに用途 |
| JPWO2013065705A1 (ja) * | 2011-10-31 | 2015-04-02 | 興和株式会社 | 粉末化粧料 |
-
2020
- 2020-02-06 CN CN202411931102.5A patent/CN119751523A/zh active Pending
- 2020-02-06 EP EP20759454.0A patent/EP3928626A4/en active Pending
- 2020-02-06 CN CN202080028448.8A patent/CN113677211A/zh active Pending
- 2020-02-06 US US17/431,825 patent/US12338264B2/en active Active
- 2020-02-06 JP JP2021501848A patent/JPWO2020170840A1/ja active Pending
- 2020-02-06 WO PCT/JP2020/004590 patent/WO2020170840A1/ja not_active Ceased
- 2020-02-13 TW TW109104490A patent/TW202045187A/zh unknown
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5856963B2 (ja) | 1977-05-06 | 1983-12-17 | 三菱化成ポリテック株式会社 | 電子発光化合物半導体の製造方法 |
| JPS637444B2 (ja) | 1980-06-30 | 1988-02-17 | Nissin Electric Co Ltd | |
| JPH03139288A (ja) | 1989-05-19 | 1991-06-13 | Hayashibara Biochem Lab Inc | α―グリコシル―L―アスコルビン酸とその製造方法並びに用途 |
| JPH03135992A (ja) | 1989-10-21 | 1991-06-10 | Hayashibara Biochem Lab Inc | 結晶2―O―α―D―グルコピラノシル―L―アスコルビン酸とその製造方法並びに用途 |
| JPH03183492A (ja) | 1989-10-21 | 1991-08-09 | Hayashibara Biochem Lab Inc | 2―O―α―D―グルコピラノシル―L―アスコルビン酸高含有物の製造方法 |
| JPH0446112A (ja) | 1990-06-11 | 1992-02-17 | Hayashibara Biochem Lab Inc | 養毛剤 |
| JPH04182419A (ja) | 1990-11-19 | 1992-06-30 | Hayashibara Biochem Lab Inc | 口腔用組成物 |
| JPH04182413A (ja) | 1990-11-19 | 1992-06-30 | Hayashibara Biochem Lab Inc | 皮膚外用剤 |
| JPH04182412A (ja) | 1990-11-19 | 1992-06-30 | Hayashibara Biochem Lab Inc | 皮膚外用剤 |
| JP3290490B2 (ja) | 1993-01-25 | 2002-06-10 | 株式会社林原生物化学研究所 | アスコルビン酸−2−O−α−グルコシドの金属塩およびその医薬用途 |
| WO2014104171A1 (ja) * | 2012-12-27 | 2014-07-03 | 株式会社林原 | アンチエイジング用皮膚外用組成物及びその製造方法 |
| WO2018021542A1 (ja) * | 2016-07-29 | 2018-02-01 | カーリットホールディングス株式会社 | 2-O-α-D-グリコシル-L-アスコルビン酸金属塩、その酸化防止剤としての用途及びその粉末の製造方法 |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP3928626A4 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023127882A1 (ja) * | 2021-12-28 | 2023-07-06 | コスメディ製薬株式会社 | スキンケア用皮膚適用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3928626A1 (en) | 2021-12-29 |
| US12338264B2 (en) | 2025-06-24 |
| TW202045187A (zh) | 2020-12-16 |
| EP3928626A4 (en) | 2022-12-07 |
| CN113677211A (zh) | 2021-11-19 |
| JPWO2020170840A1 (ja) | 2021-12-16 |
| US20220153773A1 (en) | 2022-05-19 |
| CN119751523A (zh) | 2025-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5856963B2 (ja) | 2−O−α−D−グルコシル−L−アスコルビン酸含水結晶及び2−O−α−D−グルコシル−L−アスコルビン酸含水結晶含有粉末とそれらの製造方法並びに用途 | |
| JP6555431B2 (ja) | 保湿外用剤 | |
| EP1426380B1 (en) | Association compound of trehalose or maltitol with metal ion compound | |
| WO2011036786A1 (ja) | 植物由来ポリアミン含有抽出物を有効成分するストレス軽減剤 | |
| WO2020170840A1 (ja) | 2-O-α-D-グルコシル-L-アスコルビン酸のカリウム塩結晶とその製造方法 | |
| JP2013194030A (ja) | γ−アミノ酪酸及び美白剤を含有する化粧料組成物 | |
| JP2011001313A (ja) | バイオサーファクタント及び界面活性剤を含有する組成物 | |
| TWI253931B (en) | Sebum production inhibitors | |
| JP2009234938A (ja) | 植物由来ポリアミン含有抽出物を含有する化粧品組成物 | |
| EP1460123A1 (en) | Method of sustaining aroma and use thereof | |
| WO2007077770A1 (ja) | アルキルレゾルシノール配糖体とその製造方法並びに用途 | |
| WO2024075686A1 (ja) | 皮膚常在菌叢改善剤及び皮膚外用組成物 | |
| JP2011001312A (ja) | バイオサーファクタント及び多価アルコールを含有する組成物 | |
| JP2009234937A (ja) | 植物由来ポリアミン含有抽出物を含有する化粧品組成物 | |
| JP2010018580A (ja) | ポリ−γ−L−グルタミン酸架橋体を含有する化粧品組成物 | |
| CN117243842B (zh) | 一种口感优良的多效口腔护理组合物及其应用 | |
| TW201808980A (zh) | 2-O-α-D-糖基-L-抗壞血酸金屬鹽、其作為抗氧化劑之用途及該金屬鹽之粉末之製造方法 | |
| JP2013194026A (ja) | γ−アミノ酪酸及び抗菌剤を含有する化粧料組成物 | |
| JP5650882B2 (ja) | ラジカル生成抑制剤 | |
| JP2013194029A (ja) | γ−アミノ酪酸及び抗老化剤を含有する化粧料組成物 | |
| JP3750160B2 (ja) | 非晶質性l−アスコルビン酸−2−リン酸エステル・ナトリウム塩および、その製造方法 | |
| JP2005281203A (ja) | 皮膚外用剤、ならびにグラブリジン配糖体及びその製造方法 | |
| JP2010018576A (ja) | ポリ−γ−L−グルタミン酸架橋体を含有する化粧品組成物 | |
| JP2020050598A (ja) | 水性組成物 | |
| JP2005281204A (ja) | 皮膚外用剤及びエラグ酸のα−配糖体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20759454 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2021501848 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2020759454 Country of ref document: EP Effective date: 20210920 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 17431825 Country of ref document: US |